Evidence map›Paper›PMID 41353267›Full record

ArticleNPJ biofilms and microbiomes2025

Beyond the matrix: rethinking antibiotic tolerance in CF biofilms using 3D models.

Goodness Ogechi Osondu-Chuka, Stephan Schandl, Andrea Scheberl, Olivier Guillaume, Aleksandr Ovsianikov, Erik Reimhult

Abstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Goodness Ogechi Osondu-ChukaInstitute of Colloid and Biointerface Science, BOKU University, Vienna, Austria. goodness.osondu-chuka@boku.ac.at.
Stephan SchandlResearch Group 3D Printing and Biofabrication, TU Wien, Vienna, Austria.
Andrea ScheberlInstitute of Colloid and Biointerface Science, BOKU University, Vienna, Austria.
Olivier GuillaumeResearch Group 3D Printing and Biofabrication, TU Wien, Vienna, Austria.
Aleksandr OvsianikovResearch Group 3D Printing and Biofabrication, TU Wien, Vienna, Austria.
Erik ReimhultInstitute of Colloid and Biointerface Science, BOKU University, Vienna, Austria. erik.reimhult@boku.ac.at.

Funding

Austrian Science Fund P33226
6 · The paper itself

Abstract

Chronic lung infections in cystic fibrosis (CF) patients are associated with Pseudomonas aeruginosa biofilms exhibiting high antibiotic tolerance with no clear explanation. We investigate the role of the biofilm matrix in this antibiotic tolerance using 3D biofilm models based on acetylated alginate and DNA, mimicking mucoid biofilms. Printed from these bioinks seeded with P. aeruginosa (PAO1), these models support robust microcolony formation as observed in vivo and enable high-throughput assessment of antibiotic diffusion and efficacy. Surprisingly, antibiotic diffusion is not significantly impeded by acetylation or DNA incorporation. Despite this, bacterial tolerance increases tremendously upon encapsulation in alginate. Acetylation further enhances tolerance, particularly to tobramycin, ciprofloxacin, and colistin. The addition of DNA mitigates this effect in a drug-specific manner. While mucoid biofilms, in contrast to the biofilm models, show significant retardation of antibiotic penetration, they also get saturated with all tested antibiotics within 20 h. This demonstrates that direct interaction with alginate or DNA does not explain the slow diffusion of antibiotics in mucoid P. aeruginosa biofilms. Our findings challenge the view that diffusion limitation or antibiotics binding by biofilm exopolysaccharides dominate biofilm resilience and highlight the need to target matrix-induced bacterial adaptation in the development of antibiofilm therapies.

Indexed as

Anti-Bacterial AgentsBiofilmsCystic FibrosisPseudomonas aeruginosaAlginatesCiprofloxacinColistinHumansMicrobial Sensitivity TestsModels, BiologicalPseudomonas InfectionsTobramycinAlginatesAnti-Bacterial AgentsCiprofloxacinColistinTobramycin

Identifiers

PMID41353267
PMCPMC12770553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.